BeOne Medicines (ONC) Share-based Compensation (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Share-based Compensation of $9.3 million for Q1 2026, down 40.86% year-over-year from $15.7 million in Q1 2025, and down 98.12% quarter-over-quarter from $491.7 million in Q4 2025.
BeOne Medicines (ONC) Share-based Compensation (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Share-based Compensation for 12 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 40.86% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $504.5 million (up 3303.91% YoY), while the FY2025 annual figure was $510.9 million, changed N/A from the prior year.
- Share-based Compensation eased to $9.3 million in Q1 2026 per ONC's latest filing, from $491.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $491.7 million in Q4 2025 and bottomed at -$227.2 million in Q3 2025.
- Historically, Share-based Compensation has averaged $70.1 million across 5 years, with a median of $75.3 million in 2023.
- On a YoY basis, Share-based Compensation climbed as much as 1771.36% in 2025 and fell as far as 10645.96% in 2025.
- BeOne Medicines' Share-based Compensation stood at $78.1 million in 2022, then gained by 18.94% to $92.9 million in 2023, then sank by 131.66% to -$29.4 million in 2024, then surged by 1771.36% to $491.7 million in 2025, then sank by 98.12% to $9.3 million in 2026.
- Business Quant data shows ONC's Share-based Compensation at $9.3 million in Q1 2026, $491.7 million in Q4 2025, and -$227.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 83.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.41 Mn |
| Jun 30, 2026 | 137.41 Mn |
| Mar 31, 2026 | 9.26 Mn |
| Mar 31, 2026 | 9.26 Mn |
| Dec 31, 2025 | 491.73 Mn |
| Dec 31, 2025 | 491.73 Mn |
| Sep 30, 2025 | -227.16 Mn |
| Sep 30, 2025 | -227.16 Mn |
| Jun 30, 2025 | 230.63 Mn |
| Jun 30, 2025 | 230.63 Mn |
| Mar 31, 2025 | 15.66 Mn |
| Mar 31, 2025 | 15.66 Mn |
| Dec 31, 2024 | -29.42 Mn |
| Dec 31, 2024 | -29.42 Mn |
| Sep 30, 2024 | 2.15 Mn |
| Sep 30, 2024 | 2.15 Mn |
| Jun 30, 2024 | 26.43 Mn |
| Jun 30, 2024 | 26.43 Mn |
| Mar 31, 2024 | 839,000.00 |
| Mar 31, 2024 | 839,000.00 |